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Heterotopic bone formation in abdominal incisions 
Jonathan Charles MD Pathology* 
John A Hunt MB BCh FRCS FRCS (Edin) Surgery** 
Heterotopic bone formation in vertical abdominal wounds 
is a not infrequent and sometimes disabling complication of 
abdominal surgery, occurring predominantly in males. Exci-
sion of the bone is indicated only for marked discomfort or 
pain, usually produced by an active l(festyle. Under these cir-
cumstances, recurrence of bone following excision, would be 
highly undesirable and the prophylactic use of etidronate di-
sodium may well be indicated to prevent new bone formation, 
as demonstrated by one of our cases (Case 8 ). 
Introduction 
Heterotopic bone formation in scars of abdominal incisions 
is not a rare occurrence, yet few reports are present in the lit-
erature'·". We report 8 recent cases, all males, in one of whom 
the bone recurred after excision; in another, prophylactic treat-
ment was given to prevent recurrence of bone formation in the 
surgical wound, using etidronate disodium (EHDP: Didronel). 
We present a review of the literature regarding heterotopic 
bone formation in abdominal wounds, indications for surgery 
and possible uses of EHDP. 
Case reports 
Case 1 
A 53-year-old white male health professional underwent a 
subtotal gastrectomy for adenocarcinoma of the stomach, 
through a vertical incision. Two years later the patient died 
from metastatic disease. At autopsy, heterotopic bone forma-
tion was present in his abdominal scar. 
Case2 
A 72-year-old retired white man underwent a partial colec-
tomy for adenocarcinoma of the colon, through a vertical inci-
sion. Four months later bone formation was discovered in the 
scar and was surgically excised. 
Case3 
A 45-year-old disabled white male laborer underwent 
vagotomy and pyloroplasty for intractable duodenal ulcer, 
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through an upper midline incision. At the postoperative visit, 
induration was noted in the wound, which progressed to radio-
logically proven bone. His lifestyle was not hindered by the 
bone, which was thus left alone and has not changed in 3 
years. 
Case4 
A 69-year-old retired white man underwent palliative 
esophagectomy for advanced adenocarcinoma arising in Bar-
rett's esophagus, through an upper midline and a separate 
right thoracic incision. Six weeks later bone 5 em long was 
noted in the upper part of the vertical midline incision. This 
did not hinder him and was left alone. 
Case 5 
A 44-year-old white truck driver underwent a vagotomy, 
pyloroplasty and fundoplication for severe acid-pepsin dis-
ease, plus esophagitis. After several months, he was noted to 
have a piece of bone 3 x 2 em in size at the upper end of his 
wound, near the xiphoid process. This did not progress nor 
interfere with his activities and was left alone. 
Case6 
A 70-year-old retired white man underwent a high partial 
gastrectomy for gastric lymphoma. Two months later, in fol-
low-up, he was noted to have a piece of bone about 5 em long 
by 2-3 em wide in the upper part of his abdominal scar. His 
main activity was walking and the bone did not hinder him, so 
it was left alone. 
Case 7 
A 40-year-old white laborer underwent drainage of a pan-
creatic pseudocyst through an upper midline incision. Bone 
formation was noted 3 weeks later in the scar. The bone was 
I 0 em long and bowed anteriorly, extending from xiphoid to 
umbilicus. As he became more active, it hindered his activities 
and was excised. The bone recurred but was only about 5 em 
in length and no further surgery was performed. 
CaseS 
A 49-year-old white male plasterer underwent a cholecys-
tectomy, appendectomy and repair of an umbilical hernia 
through an upper midline incision. Bone formation was noted 
3 weeks later in the scar. The bone was large (6 x 4 x 3 em), 
bowed forward, and continuous with the xiphoid process. The 
bone interfered mechanically with movement and was painful 
(Continued on page 67) ~ 
65 
ONLY ONE H;ANTAGONIST HEALS REFLUX ESOPHAGITIS 
AT DUODENAL ULCER DOSAGE. ONLY ONE. 
Of all the H2-receptor antagonists, only Axid heals and A ..,..D® 
relieves reflux esophagitis at its standard duodenal ulcer dosage. ,...,. • ~ 
Axid, ISO mg b.i.d., relieves heartburn in 86% of patients nizatidine 
after one day and 93% after one week. 1 150 b · d mg .1 .. 
ACID TESTBI. PmENT PROVEN. 
1. Data on file, Lilly Research Laboratories. See accompanying page lor prescribing information. <i:o1991, EU uu.v AND COMPANY NZ-2947-B-249304 
AXID~) 
nizatidine capsules 
Briel Summary. ConsuH the package Insert lor 
complete prescrtblng Information. 
Indications and Usage: 1. Active duodenal ulcer-
tor up to 8 weeks of treatment at a dosage of 300 mg 
h.s. or 150 mg b.i.d. Most patients heal within 4 weeks. 
2. Maintenance thetaflt- for healed duodenal ulcer 
patients at a dosage of 150 mg h.~ at bedtime. The 
consequences of therapy with Axid for longer than 1 
year are not known. 
3. Gastroesophageal reflux disease (GERD!-for up 
to 12 weeks of treatment of endosropicalfy diagnosed 
esophagitis, irx:luding erosive arid ulcerative esophagitis, 
arid associated heartburn at a dosage of 150 mg b.i.d. 
Cotltrallldlcatlotl: Known hypersensitivity to the drug. 
Because cross sensitivity in this class of compounds has 
been observed, H,-receptor antagonisls, induding Axid, 
should not be administered to patients witll a history 
of h~ty to other H1-receptor antagonists. 
Precautions: Generat-1. Symptomatic response to nizatidine therapy does not preclude the presence 
of gastric malignancy. 
2. Dosage should be reduceid in patients with moderate to severe renal insufficiency. 
3. In patients with nonmal renal function arid uncomplicated hepatic dysfunction, the disposition of 
nizatidine is similar to that in normal subjects. 
Laboratory Tests- False-positive tests ior urobilinogen with Multistix' may OCCtJr during therapy. 
Drug tntetactions- No interactioos have been obse!ved with tlleophy11ine, clllordiazepoxide, torazepam, 
lidocaina, pheny1ofn, and warfarin. Axid does not inhibrt the cytocllrorne P-450 enzyme system: therefore, 
drug interactions mediated by inhibition of hepatic metabolism are not expected to OCCtJr. In patients given 
very high doses (3,900 mg) of aspirin daily, increased serum salicylate levels were seen when nizatidine, 
150 mg b.i.d., was administered concurrently. 
Carcinogenesis, Mutagenesis, lmpairmenl of Fe!fility-A 2-year oral carcinogenicity studly in rats with 
dooes as high as 500 mglkg/day (about eo times the recommended daily therapeutic dose) showed no evidence 
of a carcinogenic effect. There was a dose-r~ated increase in the density of enterocllrornaffin-like (ECL) cells 
in the gastrc oxyntic mucosa In a 2-year study in mice, there was no evidence of a carcinogenic effect in male 
mice, although hyperplastic nodules of the liver were increased in the high-dose males as compared with 
placebo. Female mice given the high dose of Axid (2,000 mglkglday, about 330 times the human dose) showed 
marginally statistically ~gniticant increases in hepatic carcinoma and hepatic nodular hyperplasia with no 
numerical increase seen in any of the other dose groups.The rate of hepatic carcinoma in the high-dose 
animals was within the historical control limits seen for the stran of mice used. The female mice were giV8fl 
a dose larger than the maximum tolerated dose, as indicated by ex~ve (30%) ~ght decrement as compared 
with cr~ncurrent controls and evicleoce of mild liver injury (transaminase elevations). The occurrence of a marginal 
finding at high dose only in animals given an ex~ve and SO!llEINhat hepatotoxic dose, with no evidence of a 
carcinogenic effect in rats, male mice, arid female mice (given up to 300 mglkglday, about 60 times the human 
dose), and a negative mutagenicity battery are not considered evidence of a carcinogenic potential for Axid. 
Axid was not mutageflic in a battery of tests pertorrred to evaluate its potential genetic toxicity, including 
bacterial mutabon tests, unsclleduled DNA synthesis, ~r chromatid exchange, mouse lymphoma assay, 
chromosom<l aberrabon tests, and a micronucleus test 
In a 2-generabon, perinalaf and poslnalaf fertility study in rats, doses of nizatidine up to 650 mglkglday 
proiduceid no adverse effects on the reprodoctive pertorrnance of parental animals or their progeny. 
Pregnancy- Tetatogenic Effects-Pregnancy Category C-Oral reproiduction studies in rats at doses up 
to 300 times the human dose arid in Dutch Betted rabbits at doses up to 55 times the human dose revealed no 
evidence of impaired fertility or teratogenic effect: bu~ at a dose equivaloot to 300 times the human dose, 
treated rabbits had abortions, decreased number of live fetu~ and depr~ fetal weights On intravenous 
administiration to pregnam New Zealarid White rabbits, nizatidine at 20 mglkg proiduceid cardiac entargemen~ 
coarctlbon of the aortlic ardl, and cutaneous edema in 1 fetus, and at 50 mglkg, rt produceid ventrictJiar 
anomaly, distended atidomeo, spina bitida hydrocephally, and enlarged heart in 1 fetus. There are, however, 
no adequate and well-rontrolled studies in pregnant women. tt is also not known whether nizatidine can 
cause fetal harm when administered to a pregnant woman or can affect reproiductioo capacity. Nizatidine 
should be used during pregnancy only if the potential bonefit justifies the potential risk to tile fetus. 
Nursing Molhels-Studies in lactating wornen have shown that 0.1% of an oral dose is secreted 
in human milk in proportion to plasma concentrabons. Because of growth depression in pups reared 
by treated lact!ting rats, a decision should be made whether to discontinue nur~ng or the drug, taking 
into account the importance of tile drug to tile mother. 
Peidialric Use-Safety and effoctiveness in cllildren have not been estoblisfled. 
Use in Elderly Patients- Healing rates in Blderty patients were similar to those in younger age groups 
as were the rates of adverse events and laboratory test abnormalities. Age alone may not be an important 
factor in the disposition of nizatidine. 8derly patients may have reduceid renal function. 
Adverse Reactions: Woridwide, controlled clinical trials included over 6,000 patients given nizatidine in 
studies of varying durations. Placebo-controlled trials in the United States and Canada included over 2,600 patients 
given nizatidine and over 1.700 given placebo. Amorg the adverse events in these placebo-cr~ntrolled trials, only 
anemia (0.2% YS QOAJ) and urticaria (0.5% YS 0.1%) were ~gniticarrlly more common in the nizatidine group. Of 
the adverse events that occurred at a frequency of 1% or more, there was no statistically ~gniticant difference 
lletWeen Axid and placebo in the inddence of any of these events (see package insert for compfeta information). 
A variety of tess common events were also reported; it was not possible to determine whether these 
were caused by nizatidlne. 
Hepatic-Hepatocellular injury (elevated liver enzyme tests or alkaline phosphatase) ~bly or probably 
related to nizatidine ocr;urred in some patients. In some cases, there was marked elevation (>500 fUll) in 
SGOT or SGPT and, in a ~ngte instance, SGPT was >2,000 lUlL The incidence of *vated liver enzymes 
overall and eleva!ioos of up to 3 times the upper limit of normal, however, did not significantly differ from that 
in placebo patients. All abnormalities were reve<sible after discorltinuation of Axid. Since market introduction, 
hepatitis and jaundice have been reported. Rare cases of chofestatic Of mixed hepatocellular and cllofestotic 
injury with jaundice have been reported witll reversal of tile abnormalities after discorltinuation of Axid. 
Cardiovascular-In clinical pharmacofogy stuidies, short episodes of asymptomatic ventricular tacllycardia 
OCCtJrred in 2 individuals administered Axid and in 3 untreated subjects. 
CNS-Rare cases of r~ble menial confusion have been reported. 
Endocrine-Clinical pharmacology studies aRd controlled clinical trials showed no evidence of anti-
androgenic activity due to nizatidine. Impotence and decreased libido were reported with ~milar rrequency 
by patients on nizatidine and those on placebo. Gynewmastia has been reported rar~. 
Hemarotogic-Anernia was repor1ed significantly more frequently in nizatidine than in placebo-treated 
patients. Falaf thrombocytoperna was reported in a pabont treated with nizatidine and another H1-receptor 
antagonist This patient had previouw exparienceid tllrombocytopenia white taking other drugs. Rare cases 
of thrombocytopenic puf]Jura have been reported. 
lnlegumental-Urticania was reported signiticanny more rrequently in nizatidine- than in placebo-treated 
patients. Rash and exfoliative dermatitis were also reported. 
Hypersensitivity-As with other H1-receptor antagooisls, rare cases of anaphylaxis following nizatidine 
administration have been reported. Rare episodes of hyperser1~tivity reactions (eg, broncllospasm, laryngeal 
edema, - · and eosinophilia) have been reported. 
Other-Hyperuricemia unassociated with gout or nephrofith~s was reported. Eosinopllilia, fever, and 
nausea r~ted to nizatidine have been reported. 
Overdosage: Overdoses of Axid have been reported rar~. H overdosage ocr:urs, activated cllarcoal, 
ernesi~ or lavage shouid be con-ed along with clinical monitoring and supportive therapy. The ability of 
hemod~s to remove nizatidine from the boidy has not been concf~ demoristrated: however, due to its 
large volume of distribution, nizatidine is not expected to be efficierltly removed from the body by this method. 
f'V 2093 AMP {101591) 
Additional information available ro the profession on request. 
Eli Ully and Company 
Indianapolis, Indiana 
46285 
NZ-2947-B-249304 ~ 1991, Ell LILLY AND COMPANY 
HAWAII MEDICAL JOURNAL-VOL. 51, No. 3-MARCH 1992 
HETEROTOPIC (Continued from page 65) 
Figure 1: Case 8. Mature lamellar bone with sinuses contain-
ing fat and hematopoietic tissue, bordered by dense connec-
tive tissue . No cartilage is seen in this particular section. 
(Decalcified , paraffin-embedded, hematoxylin-eosin stain; 
magnification x40) . 
during his work as a plasterer. One month prior to its surgical 
excision, the patient was placed on a daily regimen of 
Didronel , 20 mg/kg/day. This dosage was continued for 3 
months post-operation. There has been no recurrence of bone 
in the scar to date, 6 years following the excision . 
The patients were of normal weight and not obese. They 
had no prior history of bone formation in other locations. In 
all cases the surgical incisions encroached upon the xiphoid 
process and the heterotopic bone later developed in the upper 
portions of the scar - in Cases 7 and 8 the heterotopic bone 
was actually attached to the xiphoid process. The bone varied 
in length from 3 em to I 0 em. Otherwise, the scars were 
formed in a normal fashion. 
The bone removed under these circumstances showed no 
histological difference from other forms of bone and con-
tained lamellar bone, fat and hematopoietic tissue, with vary-
ing amounts of cartilage, all bordered by a rim of dense con-
nective tissue . A microscopic section of the bone removed 
from Case 8 (Fig I) together with an x-ray of the resected 
specimen is presented (Fig 2) . 
Discussion 
Heterotopic bone formation in surgical wounds of the 
abdomen occurs only in longitudinal incisions (as opposed to 
horizontal ones)r -x, thus implicating the xiphoid process or 
symphysis pubis as possible progenitors in its pathogenesis. 
The bone so formed is usually near to one of these structures, 
positioned between the anterior or posterior rectus sheath and 
the rectus abdominis muscle'-'. It presents it self anywhere 
from 3 weeks to several years following operations'-' . 
This bone formation has a distinct male preponderance'·'·'-' , 
in that by 1962 only 5 of the 92 reported cases were in 
women'. This may be due in part to the fact that abdominal 
operations using longitudinal incisions are probably more 
common in males, considering the male predilection for peptic 
ulcer disease, carcinoma of the stomach, bladder and prostate. 
Abdominal operations in females, such as hysterectomies and 
Cesarean sections are frequently performed through low hori-
(Continued) >-
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Figure 2: Case 8. An x-ray of the specimen piece of bone 
resected from the patient who had been pre-tested with EHDP. 
zontal incisions, while cholecystectomies are often performed 
through oblique transverse subcostal incisions, away from the 
costal margin . If bone did form in such incisions, it would 
very likely not inconvenience the patient, and may in fact not 
even be noticed . 
There does not appear to be any evidence of a familial pre-
disposition to this type of bone formation, though it has been 
reported in 2 brothers during the same time period' . 
There are basically 2 theories regarding the pathogenesis of 
heterotopic bone formation in surgical wounds '·". One theory 
suggests that osteoblasts are derived through metaplasia of 
multi-potential mesenchymal cells already present in the fas-
cia, or derived from granulation tissue. The second theory 
postulates that transposition of periosteal or perichondral frag-
ments, disrupted at the time of surgery, will form a nidus for 
further bone growth. We do not see these processes as mutual-
68 
ly exclusive and it is our belief that either of these modes of 
bone formation may occur, separately or together, keeping in 
mind that the linea alba is possibly a vestigial remnant of the 
sternum. There is no evidence linking heterotopic bone forma-
tion to any metabolic or endocrine disorder, nor to the nature 
of the suture material used''. 
The cure for heterotopic bone formation in surgical wounds 
nas generally been surgical excision, with occasional postop-
erative radiation''·'·''. However, we now propose a possible pre-
ventive measure with the use of etidronate disodium (EHDP). 
EHDP is the only drug of its class of compounds - biphos-
phonates (formerly diphosphonates) - currently on the mar-
ket. Biphosphonates are structural analogs of pyrophosphate, a 
naturally occurring inhibitor of bone formation . EHDP pre-
vents the conversion of amorphous calcium phosphate to crys-
talline hydroxyapatite, the mineral component of bone. Fur-
thermore, it also binds to the hydroxyapatite present, render-
ing it more resistant to chemical attack by alkaline and acid 
phosphatases produced by the osteoblasts and osteoclasis 
respectively"·". It thus slows down both the dissolution and 
the accumulation of mineral. Also, it appears to interfere with 
the conversion of osteoblasts to osteocytes and markedly 
reduces the osteoclast population' "· "·'". Serum calcium and 
parathyroid hormone levels are not significantly changed", yet 
in Paget's Disease a marked decrease in both urinary hydrox-
yproline and serum alkaline phosphatase is noted, reflecting 
decreased osteoclastic and osteoblastic activity'"·"'. In short, 
EHDP inhibits both bone remodeling ~nd mineralization. 
The principal use of EHDP is in the treatment of Paget's 
Disease"·'7. It has also been recommended for heterotopic 
ossification in patients following severe head or spinal cord 
injury and following total hip arthroplasty''·'"·"". EHDP has 
also been used with varying success in postmenopausal osteo-
porosis, myositis ossificans progressiva1 1.11, calcinosis univer-
salis1', the prevention of periodontosis'", and the prevention of 
calculi in the urinary tract';. On an investigational basis, it has 
been studied for the prevention of atherosclerosis1". Recently, 
the intravenous administration of dichloromethylene diphos-
phonate (not currently on the market) and EHDP have shown 
great promise in lowering the serum calcium in patients with 
hypercalcemia of malignancym'. 
The side effects of EHDP therapy are usually manifested 
only when large or prolonged doses are administered, consist-
ing of gastrointestinal upsets"· '", osteomalacia (with increased 
likelihood of pathologic fractures)"·'"·'7, hyperphospha-
temia"·'", and an increase in bone pain'"·". 
Apart from its primary use in Paget's Disease, EHDP 
exerts its most beneficial effect in the prevention of hetero-
topic bone formation before its actual onset, rather than as 
treatment'"·'". 
Two of our patients (Cases 7 and 8) experienced severe 
pain and inconvenience from the large ossified fragments in 
their abdominal wounds. Since in each patient the heterotopic 
bone was attached to the xiphoid process, there was consider-
able limitation of their activities as construction workers. It is 
known that trauma and heavy physical labor can predispose to 
heterotopic bone formation'. With these considerations in 
mind, and after the bone recurred in Case 7, the next patient 
(Case 8) received pre- and postoperative EHDP and has not 
had a recurrence of heterotopic bone formation after 6 years. 
HAWAII MEDIC1 L JOURNAL-VOL. 51, No. 3-MARCH 1992 
REFERENCES 
I. Tama L: Heterotopic bone formation in abdominal surgical scars: a repon 
of two cases in brothers. lAMA 1966, 197(3 ): I 51-153. 
2. Sanders RL: Bone formation in upper abdominal scars. Ann Surx 
1955:141 (5):621-626. 
3. Classen KL, Wiederanders RE. Herrington JL Jr.: Heterotopic bone forma-
tion developing in abdominal scars. Swx 1960.47(6):91lS-923. 
4. Walkins GL: Bone formation in abdominal scars after xiphoideclomy. 
Arch Surx 1964:X9:731-734. 
5. Lehrman A, Pratt. JH, Parkhill EM: Heterotopic bone in laparotomy scars. 
Am J S111x 1962: I 04-591-596. 
6. Eidelman A, Waron M: Heterotopic ossilication in abdominal operation 
scars. Arch Surg 1973:107:87-lSS. 
7. Marteinsson BTH. Musgrove JE: Heterotopic bone formation in abdomi-
nal incisions. Am J Surx 1975.130:23-25. 
8. Aposlolidis NS, Legakis NC. Gregoriadis GC e1 al: Heterotopic bone for-
mation in abdominal operation scars. Repon of six cases with review of 
the literature. Am J S:trg 1981. 142:555-559. 
9. Spencer GR: Heterotopic bone formation in abdominal incisions. JR Col/ 
Surg Edinb 19X2.27(4):245-6. 
10. Soren A, Waugh TR: The morphologic and pathogenetic bases of hetero-
topic bone formation in the extremities. Zentra/hl Allg ?athol 
1983,127:91-96. 
II. Puzas JE, Miller MD, Rosier RN: Pathologic bone formation. C/in Orthop 
Rei Res 1989,245:269-2!1 I. 
12. Heaney RP, Suville PD: Etidronale disodium in postmenopausal osteo-
porosis. Clin 1'/wrnwco/ Ther 1976,20(5):593-604. 
13. Plasmans CMT. Juypers W, Slooff TJJH : The eiTecl of ethane-1-hydroxy-1, 
1-diphosphonic acid (EHDP) on matrix indirced ectopic bone formation. 
Clin Ortop 197!\, I 32:233-243. 
14. Alexandre CM, Chaping MC. Vignon Eel al: Treatment of Paget's disease 
of bone with ethane-1, hydroxy-l. 1-diphosphonale (EHDP) at a low 
dosage (5 mg/kg/day). C/in Ortlwp 1983,174: 193-205. 
15. Basic MF, Rebel A, Renier JC el al: Bone tissue in Paget's disease treated 
by elhanc-1. hydroxy-l, 1-diphosphonate (EHDP). Structure. ultrastruc-
ture, and immunocytology. Clin Ortlwp 1984, I H4:281-2XB. 
16. Krane SM: Etidronale disodium in the treatment of Paget's disease of 
bone. Ann intern Med 1982,96(5):619-625. 
17. Merkow RL, Lane JM: Current concepts of Paget's disease of bone. 
Orthop C/in N A mer 19X4, 15(4):747-763. 
Ill. Garland DF. Alday B, Venos KG, Yogi JC: Diphosphonale treatment for 
heterotopic ossification in spinal cord injury patients. Clin Ortlwp 
19X3. 176:197-200. 
19. Thomas BJ. Amstutz HC: Results of the administration of diphosphonate 
for the prevention of heterotopic ossilication after total hip arthroplasty. J 
Bone Joint Stu;~ 1985.67A(3):400-403. 
20. Spielman G, Gennarelli TA , Rogers CR: Disodium etidronate: its role in 
preventing heterotopic ossilication in severe head injury. Arch Phn Med 
Relwbil 1983.64:539-542. 
21. Ellioll DF: Fibrudysplasia ossificans progressiva (FOP) treated with 
diphosphonalc. Birth De{i'ct.l· 1974. I 0:515-520. 
22. Smith R, Russell RGG, Woods CG: Myositis ossificans progressiva. J 
Bone Joint Surg 1976.5XI3:48-57. 
23. Cram RL Barmada R. Geho WB, Ray RD: Diphosphonale treatment of 
calcinosis univcrsalis. N t:ng J Med 1971.285: I 012-1013. 
24. Sturzenburger PO. Swancar JR. Reiter G: Reduction of dental calculus in 
humans through the use of a dentifrice containing a crystal-growth 
inhibitor. J Periodontol 1971,42:416-419. 
25. Baumann JM, Ganz U, Bisaz S. Fleisch H. Rutishauer G: Verabrcichung 
cines diphosphonalcs zur steinprophylaxe. Helv Chir Acta 
1974.41 :421424. 
26. Wagner WD. Clarkson TB, Fosler J: Contrasting effects of clhanc-1, 
hydroxy-l. 1-diphosphonale (EHDP) on the regression of two types of 
dietary-induced atherosclerosis. Atlwmsc/em.l·i.l· 1977.27:419-435. 
27. Singer FR: Role of the biphosphonale etidronatc in the therapy of cancer-
related hypercalcemia. SemOn col 1990, 17(2):34-39. 
28. Canfield RE (guest editor): Etridronate disodium: a new therapy for 
hypercalcemia of malignancy. Am J Med (Symposium) 1987 .82(2A): 1-?X. 
• 
WHEN EXPERIENCE COUNTS, 
COUNT ON HAWAIIAN TAX-FREE TRUST. 
Aquila Distributors, In;- - - - ---- - - -~ 
820 Mililani Street, Suite 400, Honolulu, Hawaii 96813 I 
.J YES, te ll me mor about how I can eam high monthly income and pay 
no Federal and State lncom tues with th Hawaiian Tu-frH TNS1. Please 
send a free prosp«tlli contain ng mll(e comple e 1ntll(mation, includmg all 
tees and rxpenses. I wtll r~ad rt carefully bef01r I invest 01 send money 
Plt!iiR! print clearly 
Nam~---------------------------------------------
A~~-------------------------------------
Ci ·--------------------- State. _____ Zrp: ------
Homr Phone: ( __ _ 
Blliiness Phone: ( __ I HMJ 
HAWAII MEDICALJouRNAL-YOL 51, No. 3-MARCH 1992 
I 
I 
I 
I 
I 
I 
I 
Hawaiian Tru 1 o .. L£d.- pe pie ou knCI'i and an 
un£ n. 
You' ll al. o enj 
a high-grade, widel diversified port~ li 
monthl di id n ** b che k, 
r rein e ted ~ r ou without <ale 
charg 
read liquidit •• 
high urrenl retum 
:l low initiaJ in Lment - I ,000 
Make an investment that you and Hawaii can 
count on. For details, talk to your broker. Or call the 
Trust toll-free today . 
1-800-228-4227 
HAWAIIAN 
TAX·FREE TRUST 
' 11Jdrr 111< cln:um , I ...WI p<lrtJUn II'O;UIIlC lt<l) b.: UbJCd In W for n:tt n 
tn\c.~tlf' " ='~h.~~: !llld di~tdrnd !'lies""' nut filC\1 and '111) v.11h intm:lil rillt llllau. · 
nom. lt~rop<tllll\ 1ft 11he "'rmtt 11<1 1 \·aluc: hkh '""Y b.: n'lo!" 0110' tlgn 
C 11192 qu•l• llt<lnbulln, Inc. 
69 
